Where is Anaquant located?

Anaquant is headquartered in Lyon, France.

How many employees does Anaquant have?

As of Jun 30, 2026, the latest employee count at Anaquant is 7.

Is Anaquant a funded company?

Anaquant is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Anaquant rank among its competitors?

Anaquant ranks 432nd amongst 512 active competitors, of which 45 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Arzeda, which secured $4.51M in Aug, 2025.

Who are the top competitors of Anaquant?

Anaquant's top competitors include Nautilus Biotechnology, Somalogic and Biognosys. Among them, Arzeda secured the most recent funding round in August, 2025.

Anaquant - 2026 Company Profile, Team & Competitors

Anaquant is an acquired company based in Lyon (France), founded in 2014 by Tanguy Fortin. It operates as a Company offering targeted protein (biologics & biomarkers) quantification services by mass spectrometry. The company has 512 active competitors, including 45 funded and 113 that have exited. Its top competitors include companies like Nautilus Biotechnology, Somalogic and Biognosys.

Company Details

ANAQUANT is a company offering targeted protein quantification services for biologics and biomarker analysis mainly in the preclinical stages by the use of mass spectrometry techniques. The company's proprietary platform targetQUANT is based on two technologies Multiple/Selected Reaction Monitoring (M/SRM) and MRM3 (an advanced version of MRM with reduced noise)for targeted quantification of one to dozen proteins in biological fluids which has 3 analyzers out of which the first one is for the selection of the peptide of interest. This method could be an alternative to ELISA and antibody-based assays, as this does not need antibody development and also uses the separation power of mass specs to select specific ions corresponding to the targeted proteins. The company also offers Shotgun proteomics (using LC-MS) and marketQUANT, an algorithm for data analysis. ANAQUANT offers biologics analysis services for Host Cell Proteins, mAbs and insulin and its analogs. Its Biomarker analysis services include Drug-Induced Kidney, Liver and Vascular Injuries, Prostate Cancer biomarkers (PSA monitoring), and Alzheimer's Disease biomarkers. ANAQUANT also offers customized services for both biologics and biomarkers.

Website: www.anaquant.com/
Email ID: *****@anaquant.com

Key Metrics

Founded Year

2014

Location

Lyon, France

Stage

Acquired

Ranked

432^nd among 512 active competitors

Employee Count

7 as on Jun 30, 2026

Similar Companies

Nautilus Biotechnology & 234 more

Exit Details

Acquired by Clean Cells (Jul 30, 2026)

View Anaquant's full profile

Anaquant got acquired by Clean Cells on Jul 30, 2026.

Click here to take a look at Anaquant's acquisition in detail

Anaquant has not raised any funding rounds yet.

The founders of Anaquant is Tanguy Fortin.

Here are the details of Anaquant's key team members:

Tanguy Fortin: Founder & CEO of Anaquant.
Contact Info: 1 email address

View details of Anaquant's Founder profiles and Board Members

Anaquant's employee count trend

Anaquant has 7 employees as of Jun 26. Here is Anaquant's employee count trend over the years:

Uncover Anaquant's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Anaquant include Nautilus Biotechnology, Somalogic and Biognosys. Here is the list of Top 10 competitors of Anaquant, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Nautilus Biotechnology 2016, Seattle (United States), Public	Developer of proteomics platform for drug development	$453M	Vulcan, Bain Capital Life Sciences & 8 others	65/100
2nd	Somalogic 1999, Boulder (United States), Acquired	Developer of protein-based assays for life science research	$664M	ProQuest Investments, ICarbonX & 27 others	64/100
3rd	Biognosys 2008, Schlieren (Switzerland), Acquired	Provider of proteomics service	$9.13M	Zurcher Kantonalbank, Syngenta Group & 6 others	63/100
4th	Solvias 1999, Kaiseraugst (Switzerland), Acquired	Developer and manufacturer of medical devices, cosmetics, agrochemicals, and chemicals	-	Water Street, Broadoak Capital Partners & 1 others	59/100
5th	Arzeda 2008, Seattle (United States), Series B	Developer of enzyme design technology to bridge the gap by creating synthetic enzymes	$95.2M	OS Fund, Conti Ventures & 22 others	58/100
6th	BioAgilytix 2008, Durham (United States), Acquired	Global bioanalytical services leader, supporting drug development across various modalities	-	GHO Capital Partners, Caledonia Private Capital ... & 2 others	57/100
7th	Amunix 2006, Mountain View (United States), Acquired	Developer of peptide-based therapeutics	$201M	Omega Funds, Viking Global Investors & 18 others	57/100
8th	A-Alpha Bio 2017, Seattle (United States), Series A	Developer of cell-based tool for the measurements of protein interactions	$45.2M	Xontogeny, OS Fund & 15 others	56/100
9th	Dynamic Biosensors 2011, Planegg (Germany), Acquired	Provides solutions for label-free molecular interaction and biophysical analysis	$5.83M	Rurode, EXTOREL & 19 others	56/100
10th	Mursla 2017, London (United Kingdom), Seed	Provider of diagnostic device for cancer detection	$547K	Future Fund, TA Ventures & 26 others	55/100
432nd	Anaquant 2014, Lyon (France), Acquired	Company offering targeted protein (biologics & biomarkers) quantification services by mass spectrometry	-	-	19/100